7 research outputs found

    Bruceloza u trudnoΔ‡i: prikazi slučaja s različitim ishodima u endemskom području

    Get PDF
    Different outcomes of brucellosis in pregnancy regarding the fetus/neonate and the mother are described. Medical records of five pregnant women with brucellosis were retrospectively analyzed. Patients were treated in several departments of infectious diseases in the Republic of Macedonia between 1995 and 2009. The diagnosis of brucellosis was based on clinical findings compatible with the disease supported by detection of specific antibodies. Pregnancy outcomes in patients were as follows: spontaneous abortion, intrauterine fetal death, premature delivery in two cases (one with twin pregnancy) and term delivery. One of the women experienced relapse. Follow-up results of neonates showed no infection and their normal growth and development. Brucellosis, especially if acquired in early pregnancy, can have an impact on pregnancy outcome. In endemic regions, in pregnant women with persisting fever and unspecific manifestations one should always have in mind brucellosis. In these areas, cases with unexplained spontaneous abortion, intrauterine fetal death and premature delivery should also be investigated for brucellosis.Opisuju se različiti ishodi bruceloze u trudnoΔ‡i u odnosu na fetus/novoroΔ‘enče i majku. Retrospektivno su analizirani medicinski zapisi za pet trudnica s brucelozom. Bolesnice su liječene u nekoliko klinika za zarazne bolesti u Republici Makedoniji u razdoblju od 1995. do 2009. godine. Dijagnoza bruceloze temeljena je na kliničkim nalazima sukladnima s boleΕ‘Δ‡u i potkrijepljena otkrivanjem specifičnih protutijela. Ishodi trudnoΔ‡e u ovih bolesnica bili su sljedeΔ‡i: spontani pobačaj, intrauterina smrt fetusa, prijevremeni poroΔ‘aj u dva slučaja (jedan s blizanačkom trudnoΔ‡om) i terminski poroΔ‘aj. Recidiv je nastupio kod jedne od ovih ΕΎena. Rezultati praΔ‡enja novoroΔ‘enčadi pokazali su odsutnost infekcije te normalan rast i razvoj. Bruceloza, osobito ako je stečena u ranoj trudnoΔ‡i, moΕΎe utjecati na ishod trudnoΔ‡e. U endemskim područjima brucelozu treba uvijek imati na umu kod trudnica s ustrajnom groznicom i nespecifičnim manifestacijama. U ovim područjima testiranje na brucelozu treba provoditi i u slučaju neobjaΕ‘njenog spontanog pobačaja, intrauterine smrti fetusa i prijevremenog poroΔ‘aja

    ΠŸΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡΠ° Π½Π° Hepatitis B кај Π΄Π΅Ρ†Π° Ρ€ΠΎΠ΄Π΅Π½ΠΈ ΠΎΠ΄ HBsAg ΠΏΠΎΠ·ΠΈΡ‚ΠΈΠ²Π½ΠΈ мајки Π²ΠΎ MСдицински Ρ†Π΅Π½Ρ‚Π°Ρ€ Π²ΠΎ Π¨Ρ‚ΠΈΠΏ

    Get PDF
    Π¦Π΅Π» Π½Π° Ρ‚Ρ€ΡƒΠ΄ΠΎΡ‚: ΠŸΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡΠ° Π½Π° Π²Π΅Ρ€Ρ‚ΠΈΠΊΠ°Π»Π½Π° Ρ‚Ρ€Π°Π½ΡΠΌΠΈΡΠΈΡ˜Π° Π½Π° Hepatitis B. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΡ˜Π°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈ: Π”Π΅Ρ†Π°Ρ‚Π° Ρ€ΠΎΠ΄Π΅Π½ΠΈ ΠΎΠ΄ HBsAg ΠΏΠΎΠ·ΠΈΡ‚ΠΈΠ²Π½ΠΈ мајки вСднаш ΠΏΠΎ ΠΏΠΎΡ€ΠΎΠ΄ΡƒΠ²Π°ΡšΠ΅Ρ‚ΠΎ сС тСстирани Π·Π° ΡƒΡ‚Π²Ρ€Π΄ΡƒΠ²Π°ΡšΠ΅ присуство Π½Π° HBsAg со ΠœΠΈΠΊΡ€ΠΎΠ΅Π»ΠΈΡΠ° тСст ΠΎΠ΄ Ρ‚Ρ€Π΅Ρ‚Π° Π³Π΅Π½Π΅Ρ€Π°Ρ†ΠΈΡ˜Π° (Organon Teknika). Како ΠΏΠΎΡ‚Π²Ρ€Π΄Π΅Π½ тСст Π΅ користСн Lia Tek HCV (Organon Teknika). НарСднитС Ρ‚Π΅ΡΡ‚ΠΈΡ€Π°ΡšΠ° сС ΠΈΠ·Π²Ρ€ΡˆΠ΅Π½ΠΈ ΠΏΡ€Π΅Π΄ Π°ΠΏΠ»ΠΈΠΊΠ°Ρ†ΠΈΡ˜Π° Π½Π° Π²Ρ‚ΠΎΡ€Π° Π΄ΠΎΠ·Π° HB Π²Π°ΠΊΡ†ΠΈΠ½Π°, ΠΏΠΎΡ‚ΠΎΠ° 1 мСсСц ΠΏΠΎ добивањС Π½Π° Π²Ρ‚ΠΎΡ€Π° ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΡ‡Π½Π° Π΄ΠΎΠ·Π°, ΠΏΠΎΡ‚ΠΎΠ° ΠΏΡ€Π΅Π΄ Π°ΠΏΠ»ΠΈΠΊΠ°Ρ†ΠΈΡ˜Π° Π½Π° Ρ‚Ρ€Π΅Ρ‚Π°Ρ‚Π° ΠΈ 1, 6 ΠΈ 12 мСсСци ΠΏΠΎ Ρ‚Ρ€Π΅Ρ‚Π°Ρ‚Π° ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΡ‡Π½Π° Π΄ΠΎΠ·Π°. Π‘Π΅ Π΄Π΅Ρ‚Π΅ΠΊΡ‚ΠΈΡ€Π°ΡˆΠ΅ ΠΈ присуство Π½Π° Π°Π½Ρ‚ΠΈ-HBs (Nubenco Diagnostics, Inc. One Kalisa Way, Paramus, (U.S.A.). Π Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ: ΠΎΠ΄ 1050 Ρ€Π΅Π΄ΠΎΠ²Π½ΠΎ тСстирани Π±Ρ€Π΅ΠΌΠ΅Π½ΠΈ ΠΆΠ΅Π½ΠΈ присуство Π½Π° HBsAg Π΅ ΠΎΡ‚ΠΊΡ€ΠΈΠ΅Π½ΠΎ кај 14(1,33%). Кај Π½ΠΈΡ‚Ρƒ Π΅Π΄Π½Π° ΠΎΠ΄ испитуванитС Π±Ρ€Π΅ΠΌΠ΅Π½ΠΈ Ρ“Π΅Π½ΠΈ Π½Π΅ Π΅ рСгистриран Π°ΠΊΡƒΡ‚Π΅Π½ Ρ…Π΅ΠΏΠ°Ρ‚ΠΈΡ‚, Π½ΠΈΡ‚Ρƒ ΠΏΠΎΡ€Π΅ΠΌΠ΅Ρ‚ΡƒΠ²Π°ΡšΠ΅ Π½Π° Ρ…Π΅ΠΏΠ°Ρ‚Π°Π»Π½ΠΈΠΎΡ‚ ΠΈ Снзимскиот статуст. Π’Π΅Π΄Π½Π°Ρˆ ΠΏΠΎ ΠΏΠΎΡ€ΠΎΠ΄ΡƒΠ²Π°ΡšΠ΅Ρ‚ΠΎ ситС 14 Π½ΠΎΠ²ΠΎΡ€ΠΎΠ΄Π΅Π½ΠΈ Π΄Π΅Ρ†Π° сС тСстирани Π·Π° присуство Π½Π° HBsAg. Кај Π½ΠΈΡ‚Ρƒ Π΅Π΄Π½ΠΎ Π½Π΅ Π΅ ΠΎΡ‚ΠΊΡ€ΠΈΠ΅Π½ΠΎ присуство Π½Π° HBsAg..ΠŸΠΎΡ€Π°Π΄ΠΈ Ρ‚ΠΎΠ° Π°ΠΏΠ»ΠΈΡ†ΠΈΡ€Π°Π½ΠΈ сС i.m. 0,5 ml ) ENGERIX Π³Π΅Π½Π΅Ρ‚ΠΈΡ‡ΠΊΠΈ ΠΏΡ€ΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½Π° HB Π²Π°ΠΊΡ†ΠΈΠ½Π°. Π‘Π΅Ρ€ΡƒΠΌ (HBIG) Π½Π΅ Π°ΠΏΠ»ΠΈΡ†ΠΈΡ€Π°Π²ΠΌΠ΅ ΠΏΠΎΡ€Π°Π΄ΠΈ нСмањС моТност ΠΎΠ΄ Π½Π°Π±Π°Π²ΠΊΠ°. Π•Π΄Π΅Π½ мСсСц ΠΏΠΎ Π°ΠΏΠ»ΠΈΠΊΠ°Ρ†ΠΈΡ˜Π°Ρ‚Π° Π½Π° Π²Ρ‚ΠΎΡ€Π°Ρ‚Π° Π΄ΠΎΠ·Π° HB Π²Π°ΠΊΡ†ΠΈΠ½Π°, ΠΏΠΎΡ‚ΠΎΠ° 1, 6 ΠΈ 12 мСсСци ΠΎΠ΄ Π°ΠΏΠ»ΠΈΠΊΠ°Ρ†ΠΈΡ˜Π°Ρ‚Π° Π½Π° Ρ‚Ρ€Π΅Ρ‚Π°Ρ‚Π° Π΄ΠΎΠ·Π° HB Π²Π°ΠΊΡ†ΠΈΠ½Π°, сСрумски ΠΏΡ€ΠΈΠΌΠ΅Ρ€ΠΎΡ†ΠΈ ΠΎΠ΄ Π½ΠΎΠ²ΠΎΡ€ΠΎΠ΄Π΅Π½ΠΈΡ‚Π΅ Π΄Π΅Ρ†Π° сС тСстирани Π·Π° ΠΎΡ‚ΠΊΡ€ΠΈΠ²Π°ΡšΠ΅ присуство Π½Π° HBsAg I anti - HBs.. Testirawata poka\aa negativni rezultati. Kaj Π½ΠΈ Π΅Π΄Π½ΠΎ ΠΎΠ΄ испитанитС Π΄Π΅Ρ†Π° Π½Π΅ Π΅ рСгисран Π°ΠΊΡƒΡ‚Π΅Π½ Ρ…Π΅ΠΏΠ°Ρ‚ΠΈΡ‚, Π½ΠΈΡ‚Ρƒ ΠΏΠΎΡ€Π΅ΠΌΠ΅Ρ‚ΡƒΠ²Π°ΡšΠ΅ Π½Π° Ρ…Π΅ΠΏΠ°Ρ‚Π°Π»Π½ΠΈΠΎΡ‚ ΠΈ Снзимскиот статус.. И ΠΏΠΎΠΊΡ€Π°Ρ˜ Π·Π°Π±Ρ€Π°Π½Π°Ρ‚Π° Π·Π° доСњС Π΄Π΅Π» ΠΎΠ΄ Π΄Π΅Ρ†Π°Ρ‚Π° сС Π΄ΠΎΠ΅Π½ΠΈ Π±Π΅Π· наша согласност. Π—Π°ΠΊΠ»ΡƒΡ‡ΠΎΠΊ: И ΠΏΠΎΠΊΡ€Π°Ρ˜ Ρ‚ΠΎΠ° ΡˆΡ‚ΠΎ Π½Π°ΡˆΠΈΡ‚Π΅ Ρ€Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ сС Ρ€Π°Π·Π»ΠΈΠΊΡƒΠ²Π°Π°Ρ‚ ΠΎΠ΄ ΠΌΠ½ΠΎΠ³Ρƒ ΠΏΠΎΠ΄Π°Ρ‚ΠΎΡ†ΠΈ Π²ΠΎ Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Π°Ρ‚Π° со иста ΠΈΠ»ΠΈ слична Ρ†Π΅Π», сСпак ΠΏΡ€Π΅ΠΏΠΎΡ€Π°Ρ‡ΡƒΠ²Π°ΠΌΠ΅ ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΡ‡Π΅Π½ Ρ‚Ρ€Π΅Ρ‚ΠΌΠ°Π½ Π½Π° ситС Π½ΠΎΠ²ΠΎΡ€ΠΎΠ΄Π΅Π½ΠΈ Π΄Π΅Ρ†Π° ΠΎΠ΄ HBsAg ΠΏΠΎΠ·ΠΈΡ‚ΠΈΠ²Π½ΠΈ мајки со HBIG I HB Π²Π°ΠΊΡ†ΠΈΠ½Π°, ΠΈ Π·Π°Π±Ρ€Π°Π½Π° Π·Π° доСњС

    ΠšΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈ карактСристики Π½Π° Ρ…ΡƒΠΌΠ°Π½Π°Ρ‚Π° Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π° кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ Π»Π΅ΠΊΡƒΠ²Π°Π½ΠΈ Π²ΠΎ ΠΈΠ½Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡ‚ΠΎ ΠΎΠ΄Π΄Π΅Π»Π΅Π½ΠΈΠ΅-Π¨Ρ‚ΠΈΠΏ

    Get PDF
    Π¦Π΅Π» Π½Π° Ρ‚Ρ€ΡƒΠ΄ΠΎΡ‚: Π”Π° ја Π΄Π΅Ρ„ΠΈΠ½ΠΈΡ€Π°ΠΌΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠ°Ρ‚Π° ΡΠΈΠΌΠΏΡ‚ΠΎΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΡ˜Π° Π½Π° Ρ…ΡƒΠΌΠ°Π½Π°Ρ‚Π° Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π° кај Π±ΠΎΠ»Π½ΠΈ Π»Π΅ΠΊΡƒΠ²Π°Π½ΠΈ Π²ΠΎ Π˜Π½Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡ‚ΠΎ ΠΎΠ΄Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π²ΠΎ Π¨Ρ‚ΠΈΠΏ. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΡ˜Π°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈ: Π’ΠΎ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ ΠΎΠ΄ 10 Π³ΠΎΠ΄ΠΈΠ½ΠΈ ΠΎΠ±Ρ€Π°Π±ΠΎΡ‚Π΅Π½ΠΈ сС 1598 Π±ΠΎΠ»Π½ΠΈ ΠΊΠΎΠΈ сС Π»Π΅ΠΊΡƒΠ²Π°Π½ΠΈ ΠΎΠ΄ Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π° ΠΈ Ρ‚ΠΎΠ° 937(58,63%) ΠΌΠ°ΠΆΠΈ ΠΈ 661 (41,37%) ΠΆΠ΅Π½ΠΈ. Π’Π΅Ρ€Π°ΠΏΠΈΡ˜Π°Ρ‚Π° Π΅ спровСдувана ΠΏΠΎ ΠΏΡ€ΠΎΡ‚ΠΎΠΊΠΎΠ»ΠΈ ΠΏΡ€Π΅ΠΏΠΎΡ€Π°Ρ‡Π°Π½ΠΈ ΠΎΠ΄ Π¦Π—Πž Π²ΠΎ Ρ‚Ρ€Π°Π΅ΡšΠ΅ ΠΎΠ΄ Π½Π°Ρ˜ΠΌΠ°Π»ΠΊΡƒ 6 Π½Π΅Π΄Π΅Π»ΠΈ. Π—Π° дијагноза Π±Π΅Π° користСни : биохСмиски тСстови, ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈ ΠΈΡΠ»Π΅Π΄ΡƒΠ²Π°ΡšΠ° (Ro, Eho, KT) I serolo[ki analizi BAB, WRIGHT,Brucela kap.).ΠŸΡ€Π΅ΠΌΠ° ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈΠΎΡ‚ Ρ‚Π΅ΠΊ ΠΈ лабораторискитС Ρ€Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ 1089 (68,1%) ΠΎΠ΄ Π±ΠΎΠ»Π½ΠΈΡ‚Π΅ Π±Π΅Π° со Π°ΠΊΡƒΡ‚Π½Π° Ρ„ΠΎΡ€ΠΌΠ° Π½Π° болСста, 338 (21,1%) субакутна ΠΈ 17 (10,8%) со Ρ…Ρ€ΠΎΠ½ΠΈΡ‡Π½Π° Ρ„ΠΎΡ€ΠΌΠ°. Кај 7,7% сС јавија Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²ΠΈ, Π° Ρ€Π΅ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΡ˜Π° кај 2,6%. Π Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ: Од ΠΎΠΏΡˆΡ‚ΠΈΡ‚Π΅ симптоми Π½Π°Ρ˜Ρ‡Π΅ΡΡ‚ΠΎ Π΄ΠΎΠΌΠΈΠ½ΠΈΡ€Π°Π°: малаксалост, студ, трСски, ΠΏΠΎΡ‚Π΅ΡšΠ΅, слаб Π°ΠΏΠ΅Ρ‚ΠΈΡ‚, Π½Π°ΠΌΠ°Π»Π΅Π½Π° Π’Π’. ΠŸΠΎΠΊΠ°Ρ‡Π΅Π½Π° Ρ‚Π΅ΠΌΠΏΠ΅Ρ€Π°Ρ‚ΡƒΡ€Π° Π½Π°Ρ˜Ρ‡Π΅ΡΡ‚ΠΎ со Ρ€Π΅ΠΌΠΈΡ‚Π΅Π½Ρ‚Π½ΠΎ-ΠΈΠ½Ρ‚Π΅Ρ€ΠΌΠΈΡ‚Π΅Π½Ρ‚Π΅Π½ ΠΊΠ°Ρ€Π°ΠΊΡ‚Π΅Ρ€ бСшС присутна кај 47 9 %,,ΠΎΠ΄ Π±ΠΎΠ»Π½ΠΈΡ‚Π΅ ΠΈ Ρ‚ΠΎΠ° Π²ΠΎΠ³Π»Π°Π²Π½ΠΎΠΌ кај Π±ΠΎΠ»Π½ΠΈ Π²ΠΎ Π°ΠΊΡƒΡ‚Π½Π°Ρ‚Π° Ρ„Π°Π·Π°. Џглобно мускулни Π±ΠΎΠ»ΠΊΠΈ Π±Π΅Π° Π½Π°Ρ˜Ρ‡Π΅ΡΡ‚ΠΎ Π½Π° Π΄ΠΎΠ»Π½ΠΈΡ‚Π΅ СкстрСмитСти ΠΈ лумбосакралната ΠΊΠΈΡ‡ΠΌΠ°, Π½ΠΎ Π³ΠΈ имашС ΠΈ Π²ΠΎ останатитС Ρ€Π΅Π³ΠΈΠΈ. Π“Π»Π°Π²ΠΎΠ±ΠΎΠ»ΠΊΠ°Ρ‚Π° бСшС присутна кај 37,2% ΠΎΠ΄ Π±ΠΎΠ»Π½ΠΈΡ‚Π΅. Π₯Π΅ΠΏΠ°Ρ‚ΠΎΠΏΠΌΠ΅Π³Π°Π»ΠΈΡ˜Π°Ρ‚Π° бСшС почСсто присутна ΠΎΠ΄ ΡΠΏΠ»Π΅Π½ΠΎΠΌΠ΅Π³Π°Π»ΠΈΡ˜Π°Ρ‚Π°, Π½ΠΎ Ρ€Π΅Ρ‚ΠΊΠΎ со ΠΏΠΎΠ·ΠΈΡ‚ΠΈΠ²Π΅Π½ Π•Ρ…ΠΎ Π½Π°ΠΎΠ΄. ΠŸΠΎΠΊΠ°Ρ‡Π΅Π½ΠΈ трансаминази имашС кај 371 (23,2%). ΠžΡ€Ρ…ΠΈΠ΅ΠΏΠΈΠ΄Π΅ΠΌΠΈΡ‚ΠΈΡ Π΅ рСгистриран кај 257 Π±ΠΎΠ»Π½ΠΈ ΠΈ Ρ‚ΠΎΠ° Π½Π°Ρ˜Ρ‡Π΅ΡΡ‚ΠΎ кај ΠΏΠΎΠΏΡƒΠ»Π°Ρ†ΠΈΡ˜Π° Π΄ΠΎ 35 Π³ΠΎΠ΄ΠΈΠ½ΠΈ. Кај 368 (23,)) Π±ΠΎΠ»Π½ΠΈ отсуствуваа ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈ смптоми, Π° сС хоспитализирани Π²Ρ€Π· основа Π½Π° ΠΏΠΎΠΊΠ°Ρ‡Π΅Π½ΠΈ врСдности Π½Π° лабораториски тСстови. ΠΠ°Ρ˜Ρ‡Π΅ΡΡ‚ΠΎ сС Ρ€Π°Π±ΠΎΡ‚ΠΈ Π·Π° Π΄Π΅Ρ†Π° ΠΎΠ΄ Ρ„Π°ΠΌΠΈΠ»ΠΈΠΈ Π²ΠΎ ΠΊΠΎΠΈ ΠΈΠΌΠ° Π±ΠΎΠ»Π½ΠΈ ΠΎΠ΄ Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π°. Π—Π°ΠΊΠ»ΡƒΡ‡ΠΎΠΊ: Π‘Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π°Ρ‚Π° Π²ΠΎ Π˜ΡΡ‚ΠΎΡ‡Π½ΠΈΠΎΡ‚ Π΄Π΅Π» Π½Π° Π Π΅ΠΏΡƒΠ±Π»ΠΈΠΊΠ° МакСдонија Π΅ чСсто Π·Π°Π±ΠΎΠ»ΡƒΠ²Π°ΡšΠ΅ со Π±ΠΎΠ³Π°Ρ‚Π° ΠΈ Ρ€Π°Π·Π½ΠΎΠ²ΠΈΠ΄Π½Π° ΡΠΌΠΏΡ‚ΠΎΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΡ˜Π° која Π±Π°Ρ€Π° комплСксСн ΠΏΡ€ΠΈΠΎΡ‚ ΠΊΠ°ΠΊΠΎ Π΄ΠΈΡ˜Π°Π³Π½ΠΎΡΡ‚ΠΈΡ‡ΠΊΠΈ Ρ‚Π°ΠΊΠ° ΠΈ тСраписки

    Π₯Π΅ΠΏΠ°Ρ‚Π°Π»Π½ΠΈ Π»Π΅Π·ΠΈΠΈ ΠΏΡ€ΠΈ Π°ΠΊΡƒΡ‚Π½Π° Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π° кај Π±ΠΎΠ»Π½ΠΈ Π»Π΅ΠΊΡƒΠ²Π°Π½ΠΈ Π²ΠΎ ΠΈΠ½Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡ‚ΠΎ ΠΎΠ΄Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΠ΄ 1986-1998 Π³ΠΎΠ΄ΠΈΠ½Π°

    Get PDF
    ПовСќС ΠΎΠ΄ 10 Π³ΠΎΠ΄ΠΈΠ½ΠΈ Ρ…ΡƒΠΌΠ°Π½Π°Ρ‚Π° Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π° прСтставува Π³ΠΎΠ»Π΅ΠΌ здравствСн ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌ Π²ΠΎ Π Π΅ΠΏΡƒΠ±Π»ΠΈΠΊΠ° МакСдонија. Π’ΠΎ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ΠΎΡ‚ ΠΎΠ΄ 1996-1998 Π³ΠΎΠ΄ΠΈΠ½Π° Π½Π° Π˜Π½Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡ‚ΠΎ ΠΎΠ΄Π΄Π΅Π»Π΅Π½ΠΈΠ΅ сС Π»Π΅ΠΊΡƒΠ²Π°Π½ΠΈ 369 Π±ΠΎΠ»Π½ΠΈ со Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π°, ΠΎΠ΄ ΠΊΠΎΠΈ 205 ΠΌΠ°ΠΆΠΈ ΠΈ 164 ΠΆΠ΅Π½ΠΈ. Π₯Π΅ΠΏΠ°Ρ‚Π°Π»Π½ΠΈ Π»Π΅Π·ΠΈΠΈ Π²ΠΎ смисол Π½Π° Hepatitis reactiva brucelogenes најдовмС кај 86 Π±ΠΎΠ»Π½ΠΈ (ΠΌΠ°ΠΆΠΈ 48, ΠΆΠ΅Π½ΠΈ 38). ΠœΠ΅Ρ“Ρƒ Π±ΠΎΠ»Π½ΠΈΡ‚Π΅ застапСни сС ситС возрасти, Π½ΠΎ Π½Π°Ρ˜Ρ‡Π΅ΡΡ‚ΠΎ ΠΎΠ²ΠΈΠ΅ ΠΏΡ€ΠΎΠΌΠ΅Π½ΠΈ сС кај ΠΏΠΎΠΏΡƒΠ»Π°Ρ†ΠΈΡ˜Π° ΠΎΠ΄ 20-60 годишна возраст. ΠšΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈΡ‚Π΅ симптоми рСгистрирани кај Π½Π°ΡˆΠΈΡ‚Π΅ Π±ΠΎΠ»Π½ΠΈ сС: ΠΈΡΡ‚ΠΎΡˆΡ‚Π΅Π½ΠΎΡΡ‚, слаб Π°ΠΏΠ΅Ρ‚ΠΈΡ‚, Π±ΠΎΠ»ΠΊΠ° Π²ΠΎ Спигастриумот кај ситС Π±ΠΎΠ»Π½ΠΈ. ΠžΡΡ‚Π°Π½Π°Ρ‚ΠΈΡ‚Π΅ симптоми: ΠΏΠΎΠΊΠ°Ρ‡Π΅Π½Π° Ρ‚Π΅ΠΌΠΏΠ΅Ρ€Π°Ρ‚ΡƒΡ€Π°, Π³Π»Π°Π²ΠΎΠ±ΠΎΠ»ΠΊΠ°, Π±ΠΎΠ»ΠΊΠΈ Π²ΠΎ Π»ΠΎΠΊΠΎΠΌΠΎΡ‚ΠΎΡ€Π½ΠΈΠΎΡ‚Π±Π°ΠΏΠ°Ρ€Π°Ρ‚, ΠΏΠΎΡ‚Π΅ΡšΠ΅, студ, трСска , ΠΏΠΎΠ²Ρ€Π°ΡœΠ°ΡšΠ΅, Ρ…Π΅ΠΏΠ°Ρ‚ΠΎΠΌΠ΅Π³Π°Π»ΠΈΡ˜Π°, сплСномСгалија, иктСрус, сС Ρ€Π°Π·Π»ΠΈΡ‡Π½ΠΎ застапСни Π²ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠ°Ρ‚Π° слика Π½Π° Π±ΠΎΠ»Π½ΠΈΡ‚Π΅. Од лабораторискитС ΠΈΡΠΏΠΈΡ‚ΡƒΠ²Π°ΡšΠ° Π³ΠΈ Π΄ΠΎΠ±ΠΈΠ²ΠΌΠ΅ слСднитС Ρ€Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ: ΡƒΠΌΠ΅Ρ€Π΅Π½ΠΎ Π·Π³ΠΎΠ»Π΅ΠΌΡƒΠ²Π°ΡšΠ΅ Π½Π° врСдноститС Π½Π° ALT ΠΈ AST, ΠΈΠΌΠ°Π°Ρ‚ ситС Π±ΠΎΠ»Π½ΠΈ, Π° ΠΏΠΎΠΊΠ°Ρ‡Π΅Π½ Π±ΠΈΠ»ΠΈΡ€ΡƒΠ±ΠΈΠ½ Π΅ рСгистриран само кај 25 Π±ΠΎΠ»Π½ΠΈ. БлСдСјки Π³ΠΈ Π±ΠΎΠ»Π½ΠΈΡ‚Π΅ дојдовмС Π΄ΠΎ слСднитС Π·Π°ΠΊΠ»ΡƒΡ‡ΠΎΡ†ΠΈ: кај Π±ΠΎΠ»Π½ΠΈ со Π°ΠΊΡƒΡ‚Π½Π° Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π° ΠΌΠΎΠΆΠ΅ Π΄Π° сС појави Hepatitis reactiva brucelogenes, кој лабораториски сС манифСстира со ΡƒΠΌΠ΅Ρ€Π΅Π½ΠΎ Π½Π°Ρ€ΡƒΡˆΡƒΠ²Π°ΡšΠ΅ Π½Π° Ρ…Π΅ΠΏΠ°Ρ‚Π°Π»Π½ΠΈΠΎΡ‚ статус (ALT, AST ΠΈ Π±ΠΈΠ»ΠΈΡ€ΡƒΠ±ΠΈΠ½), Π° ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈ со Ρ…Π΅ΠΏΠ°Ρ‚ΠΎΠΌΠ΅Π³Π°Π»ΠΈΡ˜Π° ΠΈ иктСрус. ОвиС Π½Π°Ρ€ΡƒΡˆΠ΅Π½ΠΈ лабораториски Π½Π°ΠΎΠ΄ΠΈ сС ΠΎΠ΄Ρ€ΠΆΠ°Π° Π½Π°Ρ˜ΠΌΠ°Π»ΠΊΡƒ Π΄Π²Π΅ Π½Π΅Π΄Π΅Π»ΠΈ Π½Π° Π»Π΅ΠΊΡƒΠ²Π°ΡšΠ΅Ρ‚ΠΎ Π½Π° Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π°Ρ‚Π°. Π‘Π°ΠΌΠΎ Π΅Π΄Π΅Π½ Π±ΠΎΠ»Π΅Π½ Π΅ испишан со ΠΏΠΎΠΊΠ°Ρ‡Π΅Π½ΠΈ трансаминази. ΠŸΡ€ΠΈ ΠΏΠΎΠ½Π°Ρ‚Π°ΠΌΠΎΡˆΠ½ΠΈΡ‚Π΅ ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΠΈ, Ρ…Π΅ΠΏΠ°Ρ‚Π°Π»Π½ΠΈΠΎΡ‚ статус бСшС ΡƒΡ€Π΅Π΄Π΅Π½ ΡˆΡ‚ΠΎ ΡƒΠΊΠ°ΠΆΡƒΠ²Π° Π½Π° Ρ„Π°ΠΊΡ‚ΠΎΡ‚ Π΄Π΅ΠΊΠ° Π»Π΅Π·ΠΈΠΈΡ‚Π΅ Π½Π° Ρ…Π΅ΠΏΠ°Ρ€ΠΎΡ‚ ΠΏΡ€ΠΈ Π°ΠΊΡƒΡ‚Π½Π° Π±Ρ€ΡƒΡ†Π΅Π»ΠΎΠ·Π° сС ΠΎΠ΄ Ρ‚Ρ€Π°Π½Π·ΠΈΡ‚ΠΎΡ€Π΅Π½ ΠΊΠ°Ρ€Π°ΠΊΡ‚Π΅Ρ€

    Π‘Π΅Ρ€ΠΎΠ»ΠΎΡˆΠΊΠ° дијагноза Π½Π° хСпатитис β€œΠ¦β€œ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΡ˜Π° кај Π±ΠΎΠ»Π½ΠΈ хоспитализирани Π²ΠΎ Π Π• Π½Π° мСдицински Ρ†Π΅Π½Ρ‚Π°Ρ€ Π²ΠΎ Π¨Ρ‚ΠΈΠΏ

    Get PDF
    Π¦Π΅Π» Π½Π° Ρ‚Ρ€ΡƒΠ΄ΠΎΡ‚: Π‘Π΅Ρ€ΠΎΠ»ΠΎΡˆΠΊΠ° дијагноза Π½Π° Hepatitis C вирусна ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΡ˜Π° кај Π±ΠΎΠ»Π½ΠΈ со Π·Π½Π°Ρ†ΠΈ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈ манифСстСн Ρ…Π΅ΠΏΠ°Ρ‚ΠΈΡ‚, хоспитализирани Π²ΠΎ Π˜Π½Ρ„Π΅ΠΊΡ‚ΠΈΠ±Π½ΠΎΡ‚ΠΎ ΠΎΠ΄Π΄Π΅Π»Π΅Π½ΠΈΠ΅, Π±ΠΎΠ»Π½ΠΈ со Ρ…Ρ€ΠΎΠ½ΠΈΡ‡Π½Π° Π±ΡƒΠ±Ρ€Π΅ΠΆΠ½Π° ΠΈΠ½ΡΡƒΡ„ΠΈΡ†ΠΈΠ΅Π½Ρ†ΠΈΡ˜Π° Π½Π° Ρ…Π΅ΠΌΠΎΠ΄ΠΈΡ˜Π°Π»ΠΈΠ·Π° ΠΈ Π±ΠΎΠ»Π½ΠΈ со Ρ…Π΅ΠΌΠΎΡ„ΠΈΠ»ΠΈΡ˜Π°. ΠœΠ°Ρ‚Ρ€ΠΈΡ˜Π°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈ: Π’ΠΎ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ΠΎΡ‚ ΠΎΠ΄ 1993 Π΄ΠΎ 1998 Π³ΠΎΠ΄ΠΈΠ½Π° Π²ΠΎ Ρ€Π°Π±ΠΎΡ‚Π½Π°Ρ‚Π° Π΅Π΄ΠΈΠ½ΠΈΡ†Π° Π’Ρ€Π°Π½ΡΡ„ΡƒΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ˜Π° ΠΏΡ€ΠΈ ΠœΠ΅Π΄ΠΈΡ†ΠΈΠ½ΡΠΊΠΈ Ρ†Π΅Π½Ρ‚Π°Ρ€ Π²ΠΎ Π¨Ρ‚ΠΈΠΏ тСстирани сС 256 сСрумски ΠΏΡ€ΠΈΠΌΠ΅Ρ€ΠΎΡ†ΠΈ ΠΎΠ΄ Π±ΠΎΠ»Π½ΠΈ со Π·Π½Π°Ρ†ΠΈ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈ манифСстСн Ρ…Π΅ΠΏΠ°Ρ‚ΠΈΡ‚, 51 сСрумски ΠΏΡ€ΠΈΠΌΠ΅Ρ€ΠΎΠΊ ΠΎΠ΄ Π±ΠΎΠ»Π½ΠΈ со Ρ…Ρ€ΠΎΠ½ΠΈΡ‡Π½Π° Π±ΡƒΠ±Ρ€Π΅Ρ“Π½Π° ΠΈΠ½ΡΡƒΡ„ΠΈΡ†ΠΈΠ΅Π½Ρ†ΠΈΡ˜Π° Π½Π° Ρ…Π΅ΠΌΠΎΠ΄ΠΈΡ˜Π°Π»ΠΈΠ·Π° ΠΈ 15 сСрумски ΠΏΡ€ΠΈΠΌΠ΅Ρ€ΠΎΡ†ΠΈ ΠΎΠ΄ Π±ΠΎΠ»Π½ΠΈ со Ρ…Π΅ΠΌΠΎΡ„ΠΈΠ»ΠΈΡ˜Π°. Π—Π° Π΄Π΅Ρ‚Π΅ΠΊΡ†ΠΈΡ˜Π° Π½Π° структурни ΠΈ нСструктурни Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π° нс хСпатитис Π¦ вирус Π²ΠΎ испитуванитС сСрумски ΠΏΡ€ΠΈΠΌΠ΅Ρ€ΠΎΡ†ΠΈ користСни сС Π•Π›Π˜Π‘Π тСстови ΠΎΠ΄ II ΠΈ III Π³Π΅Π½Π΅Ρ€Π°Ρ†ΠΈΡ˜Π°: ABBOTT HCV EIA 2,0 (Abbott Diagnostic, Devision Wisbaden BRD); UBI HCV EIA 4,0 (Organon teknika, United Biomedical, INC.New York-USA). Kako kΠΊΠΎΠΌΡ„ΠΈΡ€ΠΌΠ°Ρ‚ΠΈΠ²Π΅Π½ тСст Π²ΠΎ Π½Π°ΡˆΠΈΡ‚Π΅ ΠΈΡΠΏΠΈΡ‚ΡƒΠ²Π°ΡšΠ° сС ΠΊΠΎΡ€ΠΈΡΡ‚Π΅ΡˆΠ΅ Lia Tek HCV III (Organon teknika, United Biomedical, Inc. New York-USA). Π Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ: Од 156 тСстирани Π±ΠΎΠ»Π½ΠΈ со Π·Π½Π°Ρ†ΠΈ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈ манифСстСн Ρ…Π΅ΠΏΠ°Ρ‚ΠΈΡ‚ само кај 9 (5.77%) Π±Π΅Π° Π΄Π΅Ρ‚Π΅ΠΊΡ‚ΠΈΡ€Π°Π½ΠΈ Π₯Π¦Π’ Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π°. Од 51 Π±ΠΎΠ»Π΅Π½ со Ρ…Ρ€ΠΎΠ½ΠΈΡ‡Π½Π° Π±ΡƒΠ±Ρ€Π΅ΠΆΠ½Π° ΠΈΠ½ΡΡƒΡ„ΠΈΡ†ΠΈΠ΅Π½Ρ†ΠΈΡ˜Π° кај 48,1%) ΡΠ΅Ρ€ΠΎΠ»ΠΎΡˆΠΊΠΈ Π±Π΅Π° Π΄ΠΈΡ˜Π°Π³Π½ΠΎΡΡ‚ΠΈΡ†ΠΈΡ€Π°Π½ΠΈ ΠΊΠ°ΠΊΠΎ Π₯Π¦Π’ Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π° ΠΏΠΎΠ·ΠΈΡ‚ΠΈΠ²Π½ΠΈ Π±ΠΎΠ»Π½ΠΈ, Π° ΠΎΠ΄ 15 Π±ΠΎΠ»Π½ΠΈ со Ρ…Π΅ΠΌΠΎΡ„ΠΈΠ»ΠΈΡ˜Π° 14(93,3%) Π±Π΅Π° Π₯Π¦Π’ Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π° ΠΏΠΎΠ·ΠΈΡ‚ΠΈΠ²Π½ΠΈ. Π—Π°ΠΊΠ»ΡƒΡ‡ΠΎΠΊ: Π₯Спатитис Π¦ вирусната ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΡ˜Π° ΡΠ΅ΡƒΡˆΡ‚Π΅ Π½Π΅ΠΌΠ° ΠΊΠΎΠΌΠΏΠ΅Ρ‚Π½Π° лабораториска дијагноза. Π”ΠΈΡ˜Π°Π³Π½ΠΎΡΡ‚ΠΈΠΊΠ°Ρ‚Π° сС Π±Π°Π·ΠΈΡ€Π° Π½Π° Π΄ΠΎΠΊΠ°ΠΆΡƒΠ²Π°ΡšΠ΅ Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π° ΠΏΡ€ΠΎΡ‚ΠΈΠ² ΠΎΠ΄Ρ€Π΅Π΄Π΅Π½ΠΈ структурни ΠΈ нСструктурни Π°Π½Ρ‚ΠΈΠ³Π΅Π½ΠΈ. Π‘Π΅ користат ELISA, RIA I RIA testovi. Kako ΠΊΠΎΠΌΡ„ΠΈΡ€ΠΌΠ°Ρ‚ΠΈΠ²Π΅Π½ тСст сС ΠΊΠΎΡ€ΠΈΡΡ‚Π΅ΡˆΠ΅ Lia Tek HCV III. ЕдинствСн Π΄ΠΈΡ˜Π°Π³Π½ΠΎΡΡ‚ΠΈΡ‡ΠΊΠΈ тСст Π·Π° Π΄ΠΎΠΊΠ°ΠΆΡƒΠ²Π°ΡšΠ΅ Π½Π° вирусот Π΅ PCR

    Hepatitis B and C at drug addicts of i.v.drugs

    Get PDF
    Background.Hepatitis B and C virus infections in Republic of Macedonia are serious medical and social problem. Aim of the work:Incidence of Hepatitis B and C at users of intravenous drugs in the district of Stip to be really determined. Methods.48 registered users of intravenous drugs were examined in the period from 1997 to 2000. 9 of them (18.75%) are patients with emphasized clinical picture of hepatitis and were hospitalized. In making the diagnosis besides the clinical picture and standard examinations, serological detection of HBsAg and anti HCV with ELISA methods were used. Results.48 registered drug users are tested and presence of HCV antibodies is detected at 44 of them (91.6%), at the same time presence of anti HCV and HBsAg at 3 of them (6.25%), and presence of HBsAg at only 1 (2.08%). Nine patients (18.75%) are with emphasized clinical picture of hepatitis and because of that they are hospitalized. The only presence of anti HCV is detected at 6 patients (66.66%) at 2 of them (22,22%) the presence of anti HCV and HBsAg at the same time is found and the only presence of HBsAg at 1 (11,11%). There is improvement of the clinical picture and labaratory results after the hospitalization of 30 days. But the prolonged increased amounts of transaminazis and the persistent presence of HCV antibodies and HBsAg are showing the chronic virus C and B hepatitis at these drug users. Conclusion.The virus hepatitis B and C is a very frequent disease of the drug users from the district of stip. All the 48 serologicaly tested drug users are bearers of the markers of Hepatitis C and B. Manifested clinical picture is registered at 9 (18.75%) drug users. Hepatitis C is dominate among the drug users

    Epidemiological characteristics of the humane brucellosis with ill at the age of 15 treated at the infective ward in Stip

    Get PDF
    Purpose: To present the epidemiological characteristics of the humane brucellosis with ill at the age of 15 treated at the infective ward in Stip. Materials and methods: In 10 years period of time at the infective ward have been treated 1598 people who have brucellosis. From them 240(15,0%) are children at the age of 15. For diagnosis of the illness, standard clinical biochemical and serological researches have been used ( BAB, Wright, Brucella cap). Conclusion: The humane brucellosis doesn’t spare the children even from the youngest age. Dominant way of transmission is the alimentary but also the contact should not be neglected. The medical officers should work far more on the problem of rising the health culture and education of the population from the rural areas in order to learn how to protect themselves from this disease
    corecore